Skip to main content
    C

    Coherus BioSciences Inc (CHRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.51
    -0.02 (-3.73%)

    Market Cap: $81.21M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Coherus BioSciences Inc (CHRS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Coherus BioSciences reported revenue of $42.17M for the fiscal year ended Dec 31, 2025, up 59.8% from the year before. That year, net income was $168.02M with a net margin of 398.4%, operating cash flow was -$138.51M and free cash flow was -$138.51M. The quarter ended Sep 30, 2026 had revenue of $14.27M and net income of -$39.33M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $190.11M, a compound annual decline of 15.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$42.17M+59.8%67.2%-429.5%398.4%
    Dec 2024$26.39M-89.7%66.9%-756.6%108.0%
    Dec 2023$257.24M+21.9%38.2%-79.0%-92.5%
    Dec 2022$211.04M-35.4%66.8%-121.7%-138.2%
    Dec 2021$326.55M-31.4%82.4%-80.8%-87.9%
    Dec 2020$475.82M+33.6%92.1%32.9%27.8%
    Dec 2019$356.07MN/A95.2%30.3%25.2%
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$1.56M-99.2%100.0%-14918.8%-15314.0%
    Dec 2016$190.11MN/A100.0%-61.0%-67.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 489.3% from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$42.17M$26.39M$257.24M$211.04M$326.55M$475.82M$356.07M$0$1.56M$190.11M
    Cost of revenue$13.81M$8.73M$158.99M$70.08M$57.59M$37.67M$17.08M$0$0$0
    Gross profit$28.36M$17.66M$98.25M$140.96M$268.96M$438.16M$338.99M$0$1.56M$190.11M
    Research and development$108.89M$91.83M$109.44M$199.36M$363.11M$142.76M$94.19M$110.24M$162.39M$254.44M
    Operating income-$181.13M-$199.65M-$203.20M-$256.88M-$263.86M$156.32M$107.77M-$204.42M-$232.14M-$115.93M
    Net income$168.02M$28.51M-$237.89M-$291.75M-$287.10M$132.24M$89.83M-$209.41M-$238.29M-$127.79M
    EBITDA-$170.20M-$186.75M-$191.53M-$242.93M-$255.34M$163.24M$115.81M-$195.31M-$224.14M-$111.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$14.27M$14.31M$12.31M$12.75M$11.57M$10.25M$7.60M$7.73M$6.05M$10.30M$2.31M$91.52M
    Gross profit$10.18M$10.06M$8.50M$8.70M$7.85M$6.86M$4.95M$4.98M$3.32M$8.49M$869.00K$6.96M
    Operating income-$33.65M-$32.33M-$36.15M-$45.88M-$44.33M-$45.49M-$45.44M-$45.38M-$46.86M-$39.63M-$67.79M-$68.91M
    Net income-$39.33M-$20.63M-$38.33M-$37.64M-$35.53M$297.77M-$56.57M-$50.70M-$10.75M-$12.92M$102.88M-$79.65M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $38.88M by $50.00M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$258.34M$448.53M$629.60M$480.85M$679.33M$841.65M$408.93M$99.47M$162.61M$178.49M
    Current assets$206.71M$341.58M$475.63M$381.23M$602.32M$767.48M$343.01M$84.43M$145.48M$161.49M
    Cash and equivalents$88.88M$125.99M$102.89M$63.55M$417.19M$541.16M$177.67M$72.36M$126.91M$124.95M
    Total liabilities$197.33M$580.52M$823.03M$618.26M$581.61M$560.67M$303.71M$138.06M$132.08M$159.13M
    Short-term debt$1.83M$1.69M$2.15M$4.32M$3.49M$3.13M$2.20MN/A$3.29M$5.55M
    Long-term debt$37.05M$264.93M$226.89M$471.06M$408.28M$404.02M$178.39M$103.09M$101.61M$100.26M
    Shareholder equity$61.01M-$131.99M-$193.43M-$137.42M$97.73M$280.97M$105.21M-$38.59M$31.82M$20.53M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$171.10M$191.18M$266.02M$258.34M$516.52M$439.46M$371.07M$448.53M$505.00M$674.86M$763.54M$629.60M
    Total liabilities$145.85M$130.34M$187.40M$197.33M$428.75M$319.64M$554.54M$580.52M$592.97M$758.96M$845.39M$823.03M
    Cash and equivalents$53.49M$82.92M$115.24M$88.88M$103.35M$216.89M$82.41M$125.99M$97.69M$159.24M$259.77M$102.89M
    Shareholder equity$25.25M$60.84M$78.62M$61.01M$87.77M$119.83M-$183.47M-$131.99M-$87.97M-$84.11M-$81.84M-$193.43M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$138.51M-$20.44M-$174.88M-$241.12M-$37.43M$154.15M$28.36M-$159.27M-$200.29M-$252.54M
    Capital expenditures$0$0$286.00K$2.04M$1.29M$7.23M$1.82M$789.00K$4.57M$6.51M
    Free cash flow-$138.51M-$20.44M-$175.17M-$243.16M-$38.72M$146.91M$26.53M-$160.06M-$204.86M-$259.06M
    Dividends paidN/AN/AN/A$3.74M$1.75M$20.35M$72.14MN/A$0$0
    Investing cash flow$375.09M$230.32M$144.64M-$166.85M-$138.41M-$14.40M-$12.73M-$1.19M-$4.42M-$6.51M
    Financing cash flow-$273.70M-$186.97M$69.60M$54.33M$51.88M$223.95M$89.37M$105.42M$206.79M$226.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$34.02M-$62.09M-$57.89M-$19.72M-$46.34M-$46.63M-$25.83M$28.61M-$62.02M$59.73M-$46.77M-$12.94M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$34.00K
    Free cash flowN/AN/A-$57.89M-$19.72M-$46.34M-$46.63M-$25.83M$28.61M-$62.02M$59.73M-$46.77M-$12.97M
    Last 12 quarters

    Frequently Asked Questions About CHRS

    What is Coherus BioSciences' annual revenue?

    Coherus BioSciences reported revenue of $42.17M for the fiscal year ended Dec 31, 2025.

    How fast is Coherus BioSciences' revenue growing?

    Revenue was up 59.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -41.5%.

    Is Coherus BioSciences profitable?

    Yes. Coherus BioSciences reported net income of $168.02M for the fiscal year ended Dec 31, 2025, with a net margin of 398.4%.

    How much free cash flow does CHRS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$138.51M minus capital expenditures of $0 produced free cash flow of -$138.51M.

    How much debt does Coherus BioSciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $37.05M, short-term debt of $1.83M and cash and equivalents of $88.88M.